Medicamen Biotech FY26 BRSR Highlights Strong Export Reliance and Environmental Compliance
Medicamen Biotech Ltd · Others (Uncategorized) · 03 Sept 2026, 10:49 pm
Medicamen Biotech FY26 BRSR Highlights Strong Export Reliance and Environmental Compliance Medicamen Biotech reported a FY26 turnover of ₹178.84 crore and PAT of ₹9.41 crore. The pharmaceutical manufacturer generates 80% of sales from exports across 35 countries via three domestic facilities. Operations maintained zero safety incidents, zero product recalls, and zero liquid discharge. The company invested 22% of capital in R&D and increased MSME sourcing to 23%. CSR spending reached ₹25.20 lakh, with the unspent ₹6.13 lakh transferred to Schedule VII funds. A nominal ₹7,080 NSE penalty for delayed shareholding pattern filings was fully paid and regularized.
Original exchange filing (PDF)
More announcements from Medicamen Biotech Ltd
- Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 13 Nov 2026
- Financial Results - Quarter and Half year ended on September 30, 2026 · 13 Nov 2026
- MEDICAMEN BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 13 Nov 2026
- MEDICAMEN BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 13 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 13 Nov 2026
- Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve the unaudited financial .... · 13 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shivalik Rasayan Ltd & Growel Remedies Ltd · 26 Oct 2026
- Outcome of the meeting of Preferential Issue Commitee of the Board of Directors of Medicamen Biotech Limited to consider and approve the allotmentb of 5,00,000 Equity Shares pursuant to .... · 23 Oct 2026
